Lincomycin, clindamycin and their applications
Language English Country Germany Media print-electronic
Document type Journal Article, Research Support, Non-U.S. Gov't, Review
- MeSH
- Anti-Bacterial Agents biosynthesis chemistry pharmacology therapeutic use MeSH
- Antiprotozoal Agents pharmacology therapeutic use MeSH
- Bacterial Infections drug therapy microbiology MeSH
- Drug Resistance, Bacterial MeSH
- Eukaryota drug effects MeSH
- Gram-Negative Bacteria drug effects MeSH
- Gram-Positive Bacteria drug effects MeSH
- Protein Synthesis Inhibitors chemistry metabolism pharmacology therapeutic use MeSH
- Clindamycin chemistry metabolism pharmacology therapeutic use MeSH
- Humans MeSH
- Lincomycin biosynthesis chemistry pharmacology therapeutic use MeSH
- Protein Biosynthesis drug effects MeSH
- Protozoan Infections drug therapy MeSH
- Animals MeSH
- Check Tag
- Humans MeSH
- Animals MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Review MeSH
- Names of Substances
- Anti-Bacterial Agents MeSH
- Antiprotozoal Agents MeSH
- Protein Synthesis Inhibitors MeSH
- Clindamycin MeSH
- Lincomycin MeSH
Lincomycin and clindamycin are lincosamide antibiotics used in clinical practice. Both antibiotics are bacteriostatic and inhibit protein synthesis in sensitive bacteria. They may even be bactericidal at the higher concentrations that can be reached in vivo. Clindamycin is usually more active than lincomycin in the treatment of bacterial infections, in particular those caused by anaerobic species; and it can also be used for the treatment of important protozoal diseases, e.g. malaria, most effectively in combination with primaquine. Resistance to lincomycin and clindamycin may be caused by methylation of 23S ribosomal RNA, modification of the antibiotics by specific enzymes or active efflux from the periplasmic space.
References provided by Crossref.org
Mutasynthesis of lincomycin derivatives with activity against drug-resistant staphylococci
